Editorial

Should percutaneous devices be used to close a patent foramen ovale after cerebral infarction or TIA?

Approximately one third of the population has a patent foramen ovale (PFO); about the same frequency as having brown hair. Can a normal finding be important in the cause of stroke, and should it change management? In particular should we close a normal hole with an artificial device?

The incidence of PFO in patients with cerebral infarction is about 20–30%, which is similar to that in control subjects. This has been taken to imply that PFO is coincidental. However, the incidence of PFO is usually higher, about 50–60%, in cryptogenic cerebral infarcts (those associated with normal carotid ultrasonography and haematological analysis in patients with no atrial fibrillation or other clinical evidence of heart disease). Furthermore, PFOs in patients with cryptogenic stroke are larger than in patients with another potential cause for stroke and in control subjects. Finally, the recurrence rate of cryptogenic stroke is higher if a PFO is detected (14% vs. 7% per 100 patient years).

These facts suggest a role for a PFO, but to establish a high likelihood of causation requires finding a source for emboli. Unless venous investigation is conducted immediately, it is difficult to differentiate primary from secondary deep vein thrombosis (DVT). Hanna et al found a DVT in 5 of 16 patients with cryptogenic stroke compared with only 1 of 23 patients with a PFO and an additional cause for stroke and in control subjects. Finally, the recurrence rate of cryptogenic stroke is higher if a PFO is detected (14% vs. 7% per 100 patient years).

These facts suggest a role for a PFO, but to establish a high likelihood of causation requires finding a source for emboli. Unless venous investigation is conducted immediately, it is difficult to differentiate primary from secondary deep vein thrombosis (DVT). Hanna et al found a DVT in 5 of 16 patients with cryptogenic stroke compared with only 1 of 23 patients with a PFO and an additional cause for stroke and in control subjects. Finally, the recurrence rate of cryptogenic stroke is higher if a PFO is detected (14% vs. 7% per 100 patient years).

Should finding a PFO change management?

Should we treat the PFO or the thromboembolic potential or both? How often are other factors such as undetected cerebrovascular disease more important? It makes intuitive sense to give up smoking, stop taking oral contraceptives, and adopt conservative measures—for example, calf exercises on plane journeys. Many physicians do not treat further or might advise aspirin after a first cerebral event. However, should we treat with warfarin and if so why not a percutaneous device to avoid the hazards of long term warfarin?

The risk of recurrence after untreated cryptogenic stroke or transient ischaemic attack (TIA) is not certain. Estimates range from approximately 1% to 10% in the first year. However, some patients in these studies were prescribed either aspirin or an oral anticoagulant. A recurrence rate of 8% on aspirin, 3% on an oral anticoagulant but 0% on no active treatment has been reported. Recurrence is related to the combination of PFO and atrial septal aneurysm, as well as to hypertension and age.

Conclusion

The recurrence rate of cryptogenic cerebral infarction or TIA in patients with PFO is not known accurately, but there is reasonable evidence that PFO is genuinely causative in a proportion of patients. Other factors including age and hypertension also affect the rate of recurrence. Randomised trials of no treatment, aspirin, warfarin, and PFO closure are not available, and current management must be based on intuition. It is intuitively reasonable to use oral anticoagulation in patients aged < 60 years with a large PFO (> 50 microcavitations), no other likely cause of stroke, and a recurrence despite aspirin treatment. Alternatively, PFO closure could be considered in patients at high risk of haemorrhagic complications or who do not want to take warfarin, or when recurrence occurs despite adequate anticoagulation. After the initial stroke or TIA, oral anticoagulation or PFO closure could be considered if the PFO is large, if there was a Valsalva manoeuvre immediately before the event, or if there is a high risk of recurrent
DVT. I think that the long term natural history of current percutaneous devices must be observed in clinical trials before they can be recommended as a routine alternative to surgery or warfarin except in unusual individual circumstances—for example, for a patient with frequent TIAs related to an acute DVT.

J CHAMBERS
Senior Lecturer and Honorary Consultant in Cardiology,
Guy’s and St Thomas’ Hospitals,
Lambeth Palace Road, London SE1 7EH, UK


9 Mas JL, Zuber M. Recurrent cerebrovascular events in patients with patent foramen ovale, atrial septal aneurysm, or both and cryptogenic stroke or transient ischaemic attack. Am Heart J 1995;130:1083–8.

STAMPS IN CARDIOLOGY

Exercise testing

Exercise testing is seldom seen on postage stamps. The 2 centavos stamp from Cuba was released in 1971 as part of a set of seven celebrating the 10th anniversary of the first manned space flight, and shows cardiopulmonary exercise testing. A similar stamp was issued by Russia in 1980 to mark the 20th anniversary of the Gagarin Cosmonaut Training Centre. The bicycle ergometer stamp was the highest value in a set of three.

M K DAVIES
A HOLLMAN